No. 12: Baxter
2018 revenues: $11,127,000,000
R&D spend: $655,000,000
Fiscal year ending: Dec. 31, 2018
Last year’s rank: 11
Joe Almeida, chairman, president & CEO; Giuseppe Accogli, SVP & president, Americas; Laura Angelini, GM, renal care; Scott Bohaboy, SVP, finance, global business & R&D & treasurer; Wil Boren, president, advanced surgery; Dennis Crowley, SVP, business development & licensing; Stacy Eisen, SVP, global communications & president, Baxter International Foundation; David Ferguson, GM, medication delivery; Cristiano Franzi, SVP & president, EMEA; Andrew Frye, SVP & president, APAC; Heather Knight, GM, U.S. hospital products; Jacqueline Kunzler, SVP, CQO; Paul Martin, SVP & CIO; Sean Martin, SVP & GC; Jeanne Mason, SVP, HR; Ellen McIntosh, SVP & corporate secretary; Dr. Sumant Ramachandra, SVP, chief science & technology officer; Reaz Rasul, GM, acute therapies; Philippe Reale, VP, global supply chain; David Roman, VP, strategy; James Saccaro, EVP & CFO; Cathy Skala, VP, business transformation office; Brain Stevens, SVP, chief accounting officer & controller; Clare Trachtman, VP, IR; Jorge Vasseur, GM, clinical nutrition.
Baxter (NYSE:BAX) was all in on renal care during the year, looking to leverage its already significant kidney resources to exploit a CMS plan to overhaul the way kidney disease is treated in the U.S. CEO Joe Almeida pledged to invest $500 million toward increasing Baxter’s home dialysis footprint and the company inked deals with Biomérieux (to develop biomarkers for acute kidney injury) and the Mayo Clinic (for a new renal care center). Full-year profits surged 126.5% to $1.62 billion, or $2.97 per share, on sales growth of 5.4% to $11.27 billion, compared with 2017. – BP